Hikma Pharmaceuticals Plc (LON:HIK) Given Average Rating of “Buy” by Analysts
Shares of Hikma Pharmaceuticals Plc (LON:HIK) have received an average recommendation of “Buy” from the ten ratings firms that are covering the stock. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is GBX 2,544.88 ($33.22).
HIK has been the subject of several analyst reports. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, September 23rd. Barclays PLC reissued an “overweight” rating and issued a GBX 2,900 ($37.85) target price on shares of Hikma Pharmaceuticals Plc in a research note on Friday, September 9th. Numis Securities Ltd reissued a “hold” rating and issued a GBX 2,660 ($34.72) target price on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 24th. Jefferies Group decreased their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a “buy” rating for the company in a research note on Monday, September 12th. Finally, Citigroup Inc. cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) target price for the company. in a research note on Thursday, August 4th.
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 2.30% during trading on Thursday, hitting GBX 1998.00. 596,463 shares of the stock were exchanged. The firm’s 50-day moving average is GBX 2,151.51 and its 200 day moving average is GBX 2,255.68. The company’s market cap is GBX 4.52 billion. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00.
In other Hikma Pharmaceuticals Plc news, insider Said Darwazah bought 50,000 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Monday, September 26th. The stock was bought at an average price of GBX 2,078 ($27.12) per share, with a total value of £1,039,000 ($1,356,219.81). Also, insider Darwazah,Said bought 200,000 shares of Hikma Pharmaceuticals Plc stock in a transaction dated Friday, August 26th. The stock was acquired at an average cost of GBX 2,160 ($28.19) per share, with a total value of £4,320,000 ($5,638,950.53).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.